0000950170-24-010969.txt : 20240202 0000950170-24-010969.hdr.sgml : 20240202 20240202212653 ACCESSION NUMBER: 0000950170-24-010969 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240131 FILED AS OF DATE: 20240202 DATE AS OF CHANGE: 20240202 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Foster Wayne CENTRAL INDEX KEY: 0001709769 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39661 FILM NUMBER: 24593702 MAIL ADDRESS: STREET 1: 125 SUMMER STREET STREET 2: 16TH FLOOR CITY: BOSTON STATE: MA ZIP: 02110 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Atea Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001593899 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 460574869 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 225 FRANKLIN STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 857-204-8109 MAIL ADDRESS: STREET 1: 225 FRANKLIN STREET STREET 2: SUITE 2100 CITY: BOSTON STATE: MA ZIP: 02110 4 1 ownership.xml 4 X0508 4 2024-01-31 0001593899 Atea Pharmaceuticals, Inc. AVIR 0001709769 Foster Wayne 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 false true false false EVP, Chief Accounting Officer false Common Stock 2024-01-31 4 M false 33334 A 33334 D Common Stock 2024-02-01 4 S false 12477 3.8394 D 20857 D Restricted Stock Units 2024-01-31 4 M false 33334 0 D Common Stock 33334 66666 D Stock Option (Right to Buy) 4.16 2024-01-31 4 A false 120100 0 A 2034-01-30 Common Stock 120100 120100 D Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Shares were sold solely to cover taxes upon the vesting of restricted stock units pursuant to a standing Rule 10b5-1 instruction dated March 15, 2022. The original grant of 100,000 RSUs vested or will vest in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs are fully vested on January 31, 2026. The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2024 such that the option is fully vested on January 31, 2028. /s/ Andrea Corcoran, as Attorney-in-Fact for Wayne Foster 2024-02-02